

2005 SEP 15 11:42

RECEIVED
CENTRAL FAX CENTER

Katherine L. WEILAND
khw@hueschen-sage.us

US PATENT & TRADEMARK
OFFICE

SEP 08 2005

FAX TRANSMISSION

CONFIDENTIALITY NOTICE

The information contained in this facsimile transmission is CONFIDENTIAL INFORMATION WHICH ALSO MAY BE LEGALLY PRIVILEGED, intended only for the use of the individual or entity named below. Unauthorized use, disclosure or copying is strictly prohibited and may be unlawful. If you have received this communication in error, please immediately notify us by telephone and return this original message to us at the below Kalamazoo address via the United States Postal Service. Thank you.

DATE: September 8, 2005
TO: Rosa THOMAS, Esq. FAX NO.: 571-273-0559
FROM: HUESCHEN & SAGE FAX NO.: 269-382-2030
RE: U.S. Serial No. 09/936,676; Christine LIBON, et al.

RECEIVED
SEP 19 2005
OFFICE OF PETITIONS

NO. OF PAGES INCLUDING COVER SHEET: 19

Dear Ms. THOMAS:

To follow up on our conversation of this morning, we provide the following:

Response and Amendment under 37 CFR § 1.111 with two (2) month extension was timely filed under Certificate of Mailing under 37 CFR § 1.8(a) with return postal card receipt on December 1, 2003.

Petition for Revival of an Application for Patent Abandoned Unavoidably under 37 CFR § 1.37(a) was filed on December 14, 2004, a copy of which is enclosed. With the Petition for Revival, a copy of the Response and Amendment of December 1, 2003 and cancelled check No. 72085 for two month extension, a date stamped return postal card receipt indicating receipt of said Response by USPTO mailroom on December 4, 2003, were provided. The USPTO return receipt confirmation of the facsimile transmission of the Petition for Revival of December 14, 2004 is enclosed herewith.

We thank you for your assistance in this matter.

Very truly yours,

THE FIRM OF HUESCHEN AND SAGE

By: Katherine L. Weiland
Katherine L. WEILAND

SEP 08 2005

PAGE 2/19 * RCVD AT 9/8/2005 10:45:39 AM [Eastern Daylight Time] * SVR:USPTO-EF-RF-6/29 * DNS:2/30559 * CSID:2693822030 * DURATION (mm-ss):05-52

Approved for use through 07/31/2006, OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNAVOIDABLY UNDER 37 CFR 1.137(a)		Docket Number (Optional) PF 98 PCI
OFFICE		
First Named Inventor: Christine LIBON	Art Unit:	1645
Application Number: 09/936,676	Examiner:	Robert Zeman
Filed: September 14, 2001		
Title: Bacterial Membrane Fractions with Adjuvant Effect		
Attention: Office of Petitions Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		
NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (703)305-9382.		
The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.		
APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION		
NOTE: A grantable petition requires the following items:		
<ul style="list-style-type: none"> (1) Petition fee. (2) Reply and/or issue fee. (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995, and for all design applications; and (4) Adequate showing of the cause of unavoidable delay. 		
1. Petition fee		
<input type="checkbox"/> Small entity - fee \$ _____ (37 CFR 1.17(l)) Applicant claims small entity status.. See 37 CFR 1.27.		
<input checked="" type="checkbox"/> Other than small entity - fee \$ <u>110.00</u> (37 CFR 1.17(l)).		
2. Reply and/or fee		
A. The reply and/or fee to the above-noted Office action in the form of		
Response & Amendment under 37 CFR § 1.111 with 2 mo. ext. fee (identify the type of reply):		
<input checked="" type="checkbox"/> has been filed previously on <u>December 1, 2003</u>		
<input checked="" type="checkbox"/> is enclosed herewith.		
B. The issue fee of \$ _____		
<input type="checkbox"/> has been paid previously on _____		
<input type="checkbox"/> is enclosed herewith.		

RECEIVED
SEP 19 2005
OFFICE OF PETITIONS

(Page 1 of 3)

This collection of information is required by 37 CFR 1.137(a) The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/61 (11-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED
UNAVOIDABLY UNDER 37 CFR 1.137(a)**

NOTE: The following showing of the cause of unavoidable delay must be signed by all applicants or by any other party who is presenting statements concerning the cause of delay.

December 14, 2004
Date

G. PATRICK SAGE
Signature

37,710
Registration Number, if applicable

G. PATRICK SAGE
Typed or printed name

(In the space provided below, please explain in detail the reasons for the delay in filing a proper reply)

Response and Amendment under 37 CFR § 1.111 with two (2) month extension were timely filed under Certificate of Mailing under 37 CFR § 1.8(a) with return postal card receipt on December 1, 2003. A copy of said response, date stamped return postal card receipt indicating receipt by USPTO mailroom on December 4, 2003 and cancelled check no. 72085 for two (2) month extension are enclosed. As this abandonment was not only unavoidable but also the result of USPTO error, reimbursement of the entire petition fee is hereby respect fully solicited.

(Please attach additional sheets if additional space is needed.)

FEE TRANSMITTAL for FY 2005
 Effective 10/01/2004. Patent fees are subject to annual revision.

Complete if Known

Application Number	09/936,676	RECEIVED CENTRAL FAX CENTER
Filing Date	September 14, 2001	
First Named Inventor	Christine LIBON	SEP 08 2005
Examiner Name	Robert ZEMAN	
Art Unit	1645	
Attorney Docket No.	PF 98 PCT SEQ	

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) \$110.00

METHOD OF PAYMENT (check all that apply)

Check Credit card Money Order Other None

Deposit Account:

Deposit Account Number: **08-3220**

Deposit Account Name: **The Firm of Hueschen and Sage**

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments

Charge any additional fee(s) or any underpayment of fee(s)

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non - English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 430	2252 215	Extension for reply within second month	
1253 980	2253 490	Extension for reply within third month	
1254 1,530	2254 765	Extension for reply within fourth month	
1255 2,080	2255 1,040	Extension for reply within fifth month	
1401 340	2401 170	Notice of Appeal	
1402 340	2402 170	Filing a brief in support of an appeal	
1403 300	2403 150	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	110.00
1453 1,370	2453 685	Petition to revive - unintentional	
1501 1,370	2501 685	Utility issue fee (or reissue)	
1502 490	2502 245	Design issue fee	
1503 660	2503 330	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR § 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Statement	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 790	2809 395	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810 790	2810 395	For each additional invention to be examined (37 CFR § 1.129(b))	
1801 790	2801 395	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify) _____

SUBTOTAL (3) (\$) \$110.00

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 790	2001 395	Utility filing fee	
1002 350	2002 175	Design filing fee	
1003 550	2003 275	Plant filing fee	
1004 790	2004 395	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	

SUBTOTAL (1) (\$) _____

2. EXTRA CLAIM FEES FOR UTILITY AND

Extra Claims

Total Claims: _____ -20** = _____ X _____ = **0.00**

Independent Claims: _____ -3*** = _____ X _____ = **0.00**

Multiple Dependent: _____ = _____

Fee from below

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1202 18	2202 9	Claims in excess of 20	
1201 88	2201 44	Independent claims in excess of 3	
1203 300	2203 150	Multiple dependent claim, if not paid	
1204 88	2204 44	** Reissue independent claims over original patent	
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$) \$0.00

SUBMITTED BY

Name (Print/Type)	G. PATRICK SAGE	Registration No. (Attorney/Agent)	37,710	Telephone	269 382 0030
Signature	<i>G. Patrick Sage</i>	Date	December 14, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

State Bank of Caledonia

FIRM OF HUESCHEN & SAGE PLLC
Account: 228540
Page: 6

The Power of HUESCHEN AND SAGE PLLC ATTORNEYS AT LAW 1000 WASHINGTON BLVD WASHINGTON, DC 20001		State Bank of Caledonia 72085
13910000		
CONVOLUTION OF POWER & TRADEMARKS	\$ 420.00	
Four Hundred Twenty and 00/100ths Dollars		
CONVOLUTION OF POWER Washington, DC 20001	G. PATRICK SAGE, ATTORNEY AT LAW	
72085 12/11/2003 \$420.00		

Applicants Christine LIBON, et al.
 Title BACTERIAL MEMBRANE FRACTIONS
 WITH ADJUVANT EFFECT
 Serial No. 09/936,676
 Filing Date September 14, 2001
 Art Unit
 Examiner Robert A. ZEMAN, Esq.

RECEIVED
 DEC 0 8 2003
 The Firm of
HUESCHEN AND SAGE

The USPTO mailroom stamp affixed hereon will acknowledge receipt by Certificate of Mailing filing procedure of: Response and Amendment, Listing of Claims, Extension Fee for two (2) month's extension, return postal card receipt.

PF 98 PCT SEQ / December 1, 2003 / gpsage



CERTIFICATE OF MAILING
UNDER 37 CFR 1.8(a)

RECEIVED
CENTRAL FAX CENTER

SEP 08 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington DC 20231 on

~~1 DECEMBER 2003~~
HUESCHEN AND SAGE

~~G. PATRICK SAGE~~
Dated: ~~1 DECEMBER 2003~~

PF 98 PCT SEQ

Applicant : Christine LIBON, Nathalie CORVAIA, Thien Ngoc N'GUYEN, Alain BECK and Jean-Yves BONNEFOY
Serial No. : 09/936,676
Filed : September 14, 2001
Title : Bacterial Membrane Fractions with Adjuvant Effect
Art Unit : 1645
Examiner : Robert A. ZEMAN, Esq.

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

RECEIVED
SEP 19 2005
OFFICE OF PETITIONS

RESPONSE AND AMENDMENT UNDER 37 CFR § 1.111

Sir:

Responsive to the Office action, dated July 1, 2003, as to which the period for response has been extended by two (2) months by payment of the appropriate fee, kindly amend as follows:

IN THE CLAIMS:

See Listing of Claims attached hereto which will replace all prior versions of claims in the application.

Claims 34, 38, 41-43, 49, 50 and 72: Presently amended

1

U.S. Serial No. 09/936,676
Response and Amendment of November 18, 2003
PF 98 PCT SEQ

Claims 35, 39, 40, 44-48 and 52-54: Canceled

REMARKS

The applicants acknowledge the Office Action of July 1, 2003, with appreciation. To begin, the Office acknowledges Applicant's election of Group I, in Paper No. 5. The Office indicates the election as filed will be treated as an election *without traverse*. By designating the subject matter outside the elected group as being merely withdrawn pending notification of allowable subject matter, the applicants distinctly and affirmatively point out subject matter which they assert, upon examination will be found a part of the claimed invention. The applicants reassert their right to rejoin non-elected claims upon the identification of allowable subject matter.

Claims 34-72 are pending in the Application, of those, Claim 36, 37, and 55-71 were withdrawn from consideration. Claims 34, 35, 38-54 and 72 were rejected by the Office under 35 U.S.C §112, second paragraph, as being indefinite for failing to claim with particularity. Claims 34 and 72 were considered indefinite for use of the term "orienting". Claims 34 and 72 are presently amended to substitute the term "inducing", as kindly suggested by the Office. Additionally, Claims 34 and 72 are considered vague and indefinite for the use of the phrase "in which the Th1 response is close to or greater than the Th2 type response". Applicants note that the language "close to" finds Specificational support on page 3, lines 35-39. The language "or greater than" has been removed from the presently amended Claims 34 and 72. Additionally, Claims 34 and 72 were amended to further limit the instant invention to the use of a crude membrane fraction obtained from *K. pneumoniae* by a process of preparation, as disclosed in the Specification, which is mixed with an antigen or haptens to elicit the desired immune response.

Claim 38 was rejected for improper Markush language. The claim has been amended to conform to proper language, as kindly suggested by the Office. Similarly, Claim 51 was amended to define a proper Markush group.

Claim 41 was considered indefinite for the use of the term "capable of". Similarly, Claim 42 was considered indefinite for use of the term "derived from". Objectionable language has been removed from Claims 41 and 42, thereby providing the requested definition.

Claim 43 and Claim 48 were rejected for improper use of the language "genetic recombination". Applicants submit the language "recombinant technologies" as a more appropriate term. Using recombinant technologies for heterologous protein expression to form proteinaceous complexes finds Specificational support on page 10, lines 16-29.

Claim 49 is rejected for the language "carry the membrane fraction...in a form...which makes it possible to enhance..." Applicants have amended the claim and removed the objectional language, "makes it possible". Applicants submit that these amendments provide the requested definition.

Moving on to the prior art rejections, the Office rejects claims 34, 38-40, 44, 48 and 72 under 35 USC §102(b) as being anticipated by Rauly, et al., (Research in Immunology, Vol. 149 No. 1, pg.99, January 1998) which discloses the use of a homogeneous preparation of recombinant *K. pneumoniae* P40 protein as an immunopotentiator. When coupled to a B-cell epitope derived from RSV, the resulting complex induces a mixed Th1/Th2 response when administered to animals. The instant invention as claimed limits the Th1 type response to be close to the Th2 response, as defined in the Specification. Applicants acknowledge Rauly, et al. describes a mixed immune response following immunization with P40-hapten preparations. However, there is no disclosure of the magnitude of the Th1 response of the mixed response obtained using recombinant P40. Applicants invite the Office to consider the disclosure of the cited Binz, et al., (US Patent 6,197,929; column 10, lines 36-47, Table 4) wherein the mixed immune response following immunization with the P40-hapten is characterized in detail with respect to the antibody isotypes. The mixed immune response elicited following immunization with the P40-hapten is one in which the Th1 response, particularly IgG2a and IgG3 isotypes, is significantly less than the Th2 response, particularly IgG1 and IgG2b isotypes. Applicants submit that the Office has not made an adequate demonstration of anticipation or provided a demonstration that Rauly, et al. suggests the instant invention. Applicants have demonstrated that immunization with the instant crude membrane fraction, FMKp, elicits a preferred immune response, one in which the Th1 response is close to the Th2 response. Such Th1/Th2 profile having a Th1 specific response close to the Th2 response is desired particularly to avoid an essentially Th2 response which poses problems in subjects with allergic predisposition (pg. 2, lines 15-29 of the Specification).

Applicants also note that Rauly, et al. adeptly demonstrates carrier-related differences in the immune response generated against the same antigen or hapten. The rP40-G1' conjugate generated a mixed Th1/Th2 response, in contrast to tetanus toxoid-G1' conjugate, which induced a Th2-like type of response. Claim 34 and Claim 72 have presently been amended to further limit the instant invention to the use of a crude membrane extract from *K. pneumoniae*, FMKp, obtained by a defined process of preparation, to be used as a carrier to elicit the claimed immune response. The crude membrane preparation is materially distinct from a purified, recombinant P40 protein preparation. As demonstrated by Rauly, et al. differences in the carrier protein affect the immune response directed to a particular antigen or hapten. Consequently, the reference may not be relied upon for the teaching that *K. pneumoniae* membrane carriers can be expected to induce uniform responses, much less the instant, mixed immune response. The reference does not suggest the performance of the crude membrane fraction, FMKp, when mixed with an antigen or hapten, would result in the claimed immune response. Based upon these analyses, Applicants submit that the instant invention is not anticipated, nor made obvious by the disclosure of Rauly, et al.

The Office goes on to reject Claims 34, 38-41, 43-54, 48-49 and 72 under 35 USC §102(e) as being anticipated by Binz, et al., (US Patent 6,197,929). The reference also discloses the use of recombinant *K. pneumoniae* P40 protein as an immunopotentiator, as well as *K. pneumoniae* protein that was purified through chromatographic techniques to obtain a homogeneous P40 preparation, free from other contaminating membrane components. The immune response was evaluated following immunization with covalent P40/hapten complexes (P40ext). The Office draws attention to a Th1 response, which is generated in animals, and is exemplified by the production of a highly quantitative delayed hypersensitivity response and macrophage activation. Applicants acknowledge these analyses and further consider the indepth analysis of the antibody isotype distribution that defines a Th1 type response and a Th2 type response following P40 immunization. The reference indicates that the titer of Th1 isotype antibodies, particularly IgG2a and IgG3, is much lower than the titer of Th2 isotype antibodies, particularly IgG1 and IgG2b and IgE (column 10, lines 36-47, Table 4). This is in stark contrast to the instant invention, as recited in Claims 34 and 72, which results in a "mixed Th1/Th2 response directed against an antigen or hapten, in which response the Th1 response is close to the Th2 response" following immunization with a mixture of FMKp/hapten. The Office has not made a *prima facie* demonstration that one skilled

in the art would expect the capacity of the instant crude membrane fraction to induce the claimed response which is characterized by the distinguishing Th1/Th2 mixed response, wherein the Th1 response is close to the Th2 response. Therefore, Applicants submit that the instant invention is not anticipated, nor made obvious, by the disclosure of Binz, et al., (US Patent 6,197,929).

Finally, the applicants note again that the references cited by the Office pertain to the use of specifically P40 protein preparations which are recombinantly expressed and purified or are purified to homogeneity from *K. pneumoniae* using extensive chromatographic techniques. These preparations are materially distinct from the composition of the crude membrane preparation of the instant invention. Neither reference suggests the performance of the claimed crude membrane preparation as an immunopotentiator. The former Claims 34 and 72 are presently limited to immunization with the crude membrane fraction, mixed with an antigen or hapten, to generate a preferred type of immune response, directed against the antigen or hapten. The cited references disclose only P40 protein preparations that are covalently coupled or combined with an antigen or hapten, which are capable of inducing a mixed Th1/Th2 response. Additionally, neither reference demonstrates, nor suggests, the claimed immune response, one in which the Th1 response is close to the Th2 response, as defined in the Specification of the instant invention, can be obtained using P40 protein as a carrier.

Applicants submit that these cited references actually sustain the novelty of the instant invention. Rauly, et al. demonstrates that different carrier proteins have a differential affect on the type of immune response elicited to a singular antigen or hapten. Considering Binz, et al. the immune response elicited by immunization with purified P40 teaches away from the claimed mixed response of the instant invention. Neither reference suggests or anticipates the performance of the crude membrane fraction, FMKp, mixed with antigen or hapten, could elicit the preferred immune response, in which the Th1 response is close to the Th2 response. In light of these remarks, reconsideration and withdrawal of the prior art rejection is respectfully solicited.

* * * * *

Accordingly, entry of the present amendment, reconsideration of all grounds of rejection, withdrawal thereof and passage of this application to issue are all thereby respectfully solicited.

It should be apparent that the undersigned attorney has made an earnest effort to place this application into condition for immediate allowance. If he can be of assistance to the Examiner in the elimination of any possibly-outstanding insignificant impediment to an immediate allowance, the Examiner is invited to call him at his below-listed number for such purpose.

Allowance is solicited.

Respectfully submitted,
THE FIRM OF HUESCHEN AND SAGE

By: 
G. PATRICK SAGE, Attorney #37,710

Dated: 12/1/2003
Customer No.: 25,666
500 Columbia Plaza
350 East Michigan Ave.
Kalamazoo, MI 49007-3856
(269) 382-0030
GPS/KLW

Enclosure: Listing of Claims, Extension Fee (Two months) \$420.00 and Postal Card Receipt

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

Listing of Claims

Claim 34. (presently amended): A method of orienting inducing an immune response toward a Th1 type and/or mixed Th1/Th2 type response directed against an antigen or hapten, in which response the Th1 response is close to or greater than the Th2 response, comprising the step of administering to a living animal body an amount of a *Klebsiella pneumoniae* membrane fraction combined admixed with the antigen or hapten, which is effective in orienting inducing the immune response toward a Th1 type and/or mixed Th1/Th2 type response directed against the antigen or hapten, in which response the Th1 response is close to or greater than the Th2 type response, and wherein said *Klebsiella pneumoniae* membrane fraction is obtained by a process of preparation comprising a step of lysing the *Klebsiella pneumoniae* bacteria after culture and a step of separating the fraction comprising the membranes from the total lysate obtained after the step of lysing.

Claim 35. (canceled)

Claim 36. (withdrawn) The use of Claim 34, wherein the membrane fraction is prepared by a method comprising the following steps:

- a) culture of the bacteria in a culture medium allowing their growth followed by centrifugation of the culture;
- b) where appropriate, deactivation of the lytic enzymes of the bacterial pellet obtained in step a), followed by centrifugation of the suspension obtained;
- c) extraction and removal of nonmembrane proteins and of nucleic acids from the pellet obtained in step a) or b) by at least one cycle of washing the pellet in an extraction solution;
- d) digestion of the membrane pellet obtained in step c) in the presence of protease enzymes, followed by centrifugation;
- e) at least one cycle of washing of the pellet obtained in step d) in physiological saline and/or in distilled water; and
- f) ultrasonication of the pellet obtained in step e).

Claim 37. (withdrawn) The use of Claim 34, wherein the membrane fraction is prepared by a method comprising the following steps:

1

U.S. Serial No. 09/936,676
Response and Amendment of November 18, 2003
PF 98 PCT SEQ

- a) culture of the bacteria in a culture medium allowing their growth, followed, where appropriate, by centrifugation;
- b) freezing of the culture medium or of the pellet obtained in step a) followed by thawing and drying of the cells;
- c) removal, by means of a DNase, of the nucleic acids from the dry cells obtained in step b) which have been resuspended;
- d) grinding of the cells obtained in step c) and clarification of the suspension obtained;
- e) precipitation, in an acid medium, of the suspension obtained in step d) and removal of the pellet;
- f) neutralization of the supernatant obtained in step e) containing the membrane suspension, followed by dialysis and concentration of the membrane suspension; and
- g) sterilization of the concentrated membrane suspension obtained in step f).

Claim 38. (presently amended): The method of claim 34, wherein the antigen or hapten is ~~chosen from the an~~ antigen[s] or hapten[s] specific to an infectious agent or ~~from the antigen[s] is~~ associated with tumor cells.

Claim 39. (canceled)

Claim 40. (canceled)

Claim 41. (presently amended): The method of Claim 34, wherein the antigen or hapten is covalently coupled with a supporting peptide to form a complex ~~capable of specifically binding~~ that binds to mammalian serum albumin.

Claim 42. (presently amended): The method of Claim 41, wherein the supporting peptide is a peptide fragment ~~derived from~~ of the streptococcal G protein.

Claim 43. (presently amended) The method of claim 41, wherein the complex is prepared by ~~genetic recombination~~ recombinant technology.

Claim 44. (canceled)

Claim 45. (canceled)

Claim 46. (canceled)

Claim 47. (canceled)

Claim 48. (canceled)

Claim 49. (presently amended): The pharmaceutical composition of Claim 72, wherein the composition comprises an agent which ~~makes it possible to carry~~ carries the membrane fraction associated with the antigen, hapten or complex, in [a] ~~the form which makes it possible to~~ of an emulsion or encapsulated particle, ~~thereby enhance~~ enhancing its stability and /or its immunogenicity.

Claim 50. (previously presented): The pharmaceutical composition of Claim 49, wherein the agent is an oil-in-water or water-in-oil type emulsion.

Claim 51. (presently amended): The pharmaceutical composition of Claim 49, wherein the agent is a ~~particle of the liposome, a microsphere or a nanosphere type or any type of structure allowing the encapsulation and the presentation in particulate form of the membrane fraction associated with the antigen, hapten, or complex.~~

Claim 52. (canceled)

Claim 53. (canceled)

Claim 54. (canceled)

Claim 55. (withdrawn) The use of Claim 34 for the preparation of a pharmaceutical composition intended for the prevention or treatment of infectious diseases or cancers.

Claim 56. (withdrawn) The use of Claim 55, wherein the infectious disease is of viral, bacterial, fungal or parasitic origin.

Claim 57. (withdrawn) The use of Claim 56 for the preparation of a pharmaceutical composition intended for the prevention or treatment of paramyxovirus infections.

Claim 58. (withdrawn) The use of Claim 57, wherein the paramyxovirus is a respiratory syncytial virus.

Claim 59. (withdrawn) The use of Claim 58, wherein the antigen associated with the membrane fraction comprises the peptide G2Na of SEQ ID No. 4 or one of its homologs whose sequence exhibits a degree of identity of at least 80% with SEQ ID No. 4.

Claim 60. (withdrawn) The use of Claim 59, wherein the peptide G2Na or one of its homologs is covalently coupled with a C-terminal fragment (BB) of the streptococcal G protein to form a complex capable of binding to mammalian serum albumin.

Claim 61. (withdrawn) The use of Claim 57, wherein the paramyxovirus is a parainfluenzae virus.

Claim 62. (withdrawn) A pharmaceutical composition comprising a membrane fraction prepared by the method of Claim 36 and an antigen or hapten associated with the membrane fraction.

Claim 63. (withdrawn) A pharmaceutical composition comprising a membrane fraction prepared by the method of Claim 37 and an antigen or hapten associated with the membrane fraction.

Claim 64. (withdrawn) The pharmaceutical composition of Claim 62, wherein the antigen is chosen from paramyxovirus peptide fragments.

Claim 65. (withdrawn) The pharmaceutical composition of Claim 63, wherein the antigen is chosen from paramyxovirus peptide fragments.

Claim 66. (withdrawn) The pharmaceutical composition of Claim 64, wherein the paramyxovirus is a respiratory syncytial virus or a parainfluenzae virus.

Claim 67. (withdrawn) The pharmaceutical composition of Claim 65, wherein the paramyxovirus is a respiratory syncytial virus or a parainfluenzae virus.

Claim 68. (withdrawn) The pharmaceutical composition of Claim 66, wherein the antigen associated with the membrane fraction comprises the peptide G2Na of

SEQ ID No. 4 of the respiratory syncytial virus or a peptide whose sequence exhibits a degree of identity of at least 80% with SEQ ID No. 4.

Claim 69. (withdrawn) The pharmaceutical composition of Claim 67, wherein the antigen associated with the membrane fraction comprises the peptide G2Na of SEQ ID No. 4 of the respiratory syncytial virus or a peptide whose sequence exhibits a degree of identity of at least 80% with SEQ ID No. 4.

Claim 70. (withdrawn) The pharmaceutical composition of Claim 68, wherein the peptide G2Na, or one of its homologs, is covalently coupled with a C-terminal fragment (BB) of the streptococcal G protein to form a complex capable of binding to mammalian serum albumin.

Claim 71. (withdrawn) The pharmaceutical composition of Claim 69, wherein the peptide G2Na, or one of its homologs, is covalently coupled with a C-terminal fragment (BB) of the streptococcal G protein to form a complex capable of binding to mammalian serum albumin.

Claim 72. (presently amended): A pharmaceutical composition comprising a *Klebsiella pneumoniae* membrane fraction ~~combined~~ admixed with an antigen or hapten, which is effective in ~~orienting~~ inducing an immune response toward a ~~Th1 type and/or mixed Th1/Th2 type response~~ directed against the antigen or hapten, in which response the Th1 response is close to ~~or greater than~~ the Th2 type response, with a pharmaceutically acceptable carrier, diluent and/or additive, and wherein said *Klebsiella pneumoniae* membrane fraction is obtained by a process of preparation comprising a step of lysing the *Klebsiella pneumoniae* bacteria after culture and a step of separating the fraction comprising the membranes from the total lysate obtained after the step of lysing.

Auto-Reply Facsimile Transmission



TO: Fax Sender at 269 382 2030
 Fax Information
 Date Received: 12/14/2004 2:52:06 PM [Eastern Standard Time]
 Total Pages: 17 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
 Cover
 Page

DEC-14-2004 14150 HUESCHEN AND SAGE 209 382 2030 P.01

PROCESSED 11-09
 RECEIVED 04-29-05 04:52:06 PM 04/29/05
 U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNAVOIDABLY UNDER 37 CFR 1.137(a)

Control Number (Optional)
 37 CFR 1.137

First Named Inventor: **Charles LABON** Art Unit: **1645**
 Application Number: **09/036,636** Examiner: **Robert Semon**
 Filed: **September 14, 2001**
 Title: **Bacterial Membrane Fractures with Adjuvant Effect**

Attention: Office of Petitions
 Small Shop Petitions
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (703) 305-9382.

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee.
- (2) Reply and/or issue fee.
- (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995, and for all design applications; and
- (4) Adequate showing of the cause of unavoidable delay.

1. Petition fee

Small entity - fee \$ _____ (37 CFR 1.170) Applicant claims small entity status. See 37 CFR 1.27.

Other than a small entity - fee \$ 110.00 (37 CFR 1.170).

2. Reply and/or fee

A. The reply and/or fee to the above-noted Office action is in the form of

Response A, Amendment under 37 CFR 1.111 with 2 ms. ext. fee (Identify the type of reply:

has been filed previously on December 1, 2001

is enclosed herewith.

B. The issue fee of \$ _____

has been paid previously on _____

is enclosed herewith.

(Page 1 of 2)

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a patent by the public which is to be used by the USPTO. This includes an application. Confidentiality is governed by 35 U.S.C. 115 and 37 CFR 1.15. This collection is estimated to take 15 to 20 minutes to complete. Inquiries concerning this collection of information, including comments and suggestions for reducing the burden, should be directed to the Office of Management and Enterprise Services, Paperwork Reduction Project (4410-0001), Washington, DC 20503. If you have any questions regarding this collection of information, please contact the Office of Management and Enterprise Services, Paperwork Reduction Project (4410-0001), Washington, DC 20503. If you need assistance in completing this form, call 1-800-PTD-9123 and select option 2.

PAGE 1/7 RCVD AT 12/14/2004 2:52:06 PM [Eastern Standard Time] SVR:USPTO-EFXRF-6/29 DNS:2730559 CSID:269 382 2030 DURATION (mm-ss):05-21:19

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURRED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLOR OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.